close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

49.78 -9.37 (-15.84%)
Official Closing Price Updated: 7:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
46 47 Next >
Discover the most active stocks in Monday's session.
Discover the most active stocks in Monday's session. Stay informed about the stocks that are generating the most trading volume! 
Via Chartmill
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hims & Hers
From Faruqi & Faruqi, LLP
Via Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Hims & Hers Health Unusual Options Activity
 
Via Benzinga
Crude Oil Falls 1%; US Services PMI Declines In June
 
Via Benzinga
Which stocks are experiencing notable movement on Monday?
Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
Rosen Law Firm Encourages Hims & Hers Health, Inc. Investors to Inquire About Securities Class Action Investigation – HIMS
From The Rosen Law Firm, P.A.
Via Business Wire
Hims & Hers Health (HIMS) Stock Trades Down, Here Is Why
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 29.2% in the morning session after Novo Nordisk, the maker of the weight loss drug Wegovy, announced it would terminate its agreement... 
Via StockStory
Topics Economy
These stocks are gapping in today's session
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday. 
Via Chartmill
Hims & Hers Stock Plunges As Novo Nordisk Ends Partnership Over Allegations Of Selling Knockoff Versions Of Wegovy
Novo said that Hims & Hers failed to adhere to the law, which prohibits mass sales of compounded drugs. It alleged that the telehealth operator is promoting and selling illegitimate, knockoff versions... 
Via Stocktwits
Topics Law Enforcement
Hims & Hers Health Stock Is Tumbling Monday: What's Happening?
Hims & Hers Health Inc (NYSE:HIMS) shares are trading lower Monday after Novo Nordisk A/S (NYSE:NVO) terminated its collaboration with the company. 
Via Benzinga
IBD 50's Hims Plummets After Novo Yanks Deal Over 'Deceptive' And 'Illegitimate' Wegovy Knockoffs
Hims stock plummeted Monday after Novo Nordisk ended their collaboration over concerns about Hims' compounded semaglutide. 
Via Investor's Business Daily
These stocks are moving in today's pre-market session
Discover the top movers in Monday's pre-market session and stay informed about market dynamics. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
1 Profitable Stock for Long-Term Investors and 2 to Be Wary Of
A company with profits isn’t always a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory
5 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
How IBD 50's Hims & Hers Is Shaking Up The Weight-Loss Brawl
This dark horse candidate has emerged to take significant share in the weight-loss drugs space. 
Via Investor's Business Daily
1 Mid-Cap Stock for Long-Term Investors and 2 to Ignore
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from... 
Via StockStory
Where Will Hims & Hers Stock Be in 10 Years?
The market is underestimating how much potential Hims & Hers has long-term. 
Via The Motley Fool
Move Over Hims & Hers Health: This Insurance Business Could Be the Next Monster Healthcare Stock (Hint: It's Not UnitedHealth)
Hims & Hers Health shares rocketed higher over the last year, rewarding investors. 
Via The Motley Fool
Topics Government World Trade
These 2 Growth Stocks Are No-Brainer Buys Right Now
Via The Motley Fool
VF Corp, MGM Resorts, PENN Entertainment, Hims & Hers Health, and Camping World Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +1.5%, S&P 500 +1.0%) as reports pointed to easing tensions between Israel and Iran. 
Via StockStory
Topics Economy Stocks
Sage Therapeutics, Roku, EchoStar And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
1 Unpopular Stock that Deserves a Second Chance and 2 to Keep Off Your Radar
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other... 
Via StockStory
3 Reasons We Love Hims & Hers Health (HIMS)
The past six months have been a windfall for Hims & Hers Health’s shareholders. The company’s stock price has jumped 90%, hitting $57.16 per share. This was partly due to its solid quarterly results,... 
Via StockStory
Hims & Hers Stock Falls After Eli Lilly Rules Out Telehealth Tie-Up: Citi Calls It Aggressive Stance, Retail Turns Bearish
If Hims were to align with Lilly, Citi warned, it would signal the company has "thrown in the towel" on compounded medications. 
Via Stocktwits
Topics Regulatory Compliance
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Hims & Hers Stock Is Soaring Again. But Should You Buy the Stock?
Via The Motley Fool
Topics Supply Chain
Is Hims & Hers Health a Smart Buy Right Now?
Shares of Hims & Hers have crushed the market over the last year. 
Via The Motley Fool
Topics Artificial Intelligence
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
46 47 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today